Novel Prime-Boosting Regimens Involving Immunogenic Polypeptides Encoded By Polynucleotides

Patent No. EP2869841 (titled "Novel Prime-Boosting Regimens Involving Immunogenic Polypeptides Encoded By Polynucleotides") was filed by Glaxosmithkline on Jul 5, 2013. The application was issued on Aug 25, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JANSSEN VACCINES & PREVENTIONMay 24, 2022BOULT WADE TENNANT

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2869841

GLAXOSMITHKLINE
Application Number
EP13734111A
Filing Date
Jul 5, 2013
Status
Revoked
Nov 8, 2024
Publication Date
Aug 25, 2021